Management

Stephane Degove; portrait of CEO and co-founder at Atamyo Therapeutics

Stéphane Degove

Co-founder
& Chief Executive Officer

Stephane Degove; portrait of CEO and co-founder at Atamyo Therapeutics

Stéphane Degove

Co-founder & Chief Executive Officer

Stéphane is a biotech entrepreneur with a 25 years experience in pharma/biotech and strategy. He graduated from ESCP (majoring in Finance), worked at Sanofi in Finance and was co-founder and CFO in 2003 of a biotechnology company in cancer and thrombosis, Endotis Pharma. He co-founded in 2013 and was CEO of an immuno-oncology biotech, Gamamabs Pharma. Under his leadership, Endotis Pharma and GamaMabs Pharma raised € 70 million from international funds and built portfolios of innovative products developed up to Phase II.

View Bio
Isabelle Richard, portrait or Chief Scientific Advisor and co-founder at Atamyo

Isabelle Richard, Ph. D

Co-founder
& Chief Scientific Officer

Isabelle Richard, portrait or Chief Scientific Advisor and co-founder at Atamyo

Isabelle Richard, Ph. D

Co-founder & Chief Scientific Officer

Dr. Isabelle RICHARD is a research Director at the CNRS. She is heading the Muscular Dystrophy team within the INSERM unit U951 at Genethon, Evry, France. Isabelle Richard is an expert in neuromuscular diseases and a pioneer in the research on LGMDs and in the development of gene therapy targeting LGMDs. She has published more than 160 scientific papers on muscular dystrophies. Among the most important highlights: identification of calpain 3 as the first gene implicated in an LGMD, demonstration of the heterogeneity of this group of diseases, participation in the identification of the gene of all the frequent LGMDs, proof-of-principle of the efficiency of gene therapy for all the most frequent LGMDs.

View Bio

Sophie Olivier, MD

Chief Medical Officer

Sophie Olivier, MD

Chief Medical Officer

Sophie Olivier, MD, is responsible for clinical development strategy. Dr. Sophie Olivier has extensive clinical development experience in large and small pharma organizations and has overseen multiple regulatory interactions with both the FDA and the EMA. Prior to joining Atamyo, Dr. Olivier was Chief Medical Officer at Genticel (2014-2017) and more recently at Lysogene (2017-2021). In her position at Lysogene, Sophie Olivier oversaw clinical development of AAV gene therapies in rare neurodegenerative pediatric diseases. Before joining Genticel, Dr. Olivier worked as Scientific Officer in the Pediatric Team at the European Medicines Agency in London and led clinical developments in Women’s Health diseases at Wyeth Pharmaceutical, US (2000-2009). Dr. Sophie Olivier obtained MD degree and board certification in Obstetrics and Gynecology (summa cum laude) from the University of Marseille, France and M.Sc. in Biology of Reproduction from the University of Paris, France.

View Bio

Board of Directors

Frédéric Revah, Ph.D., CEO,

Genethon

Alexandre Lemoalle, Director of Strategic Projects,

Genethon

Stéphane Degove, CEO,

Atamyo